Grifols (NASDAQ: GRFS) — Perfil da empresa, notícias e dados financeiros
Grifols specializes in biotherapeutics, producing life-saving treatments derived from plasma to enhance patient health globally.
Grifols
Grifols is a global healthcare company specializing in the development, production, and distribution of plasma-derived medicines and biopharmaceutical solutions. Founded in Barcelona, the company operates across four primary business segments: Biopharma, Diagnostic, Bio Supplies, and Healthcare Solutions. It manufactures treatments for rare, chronic, and life-threatening conditions in therapeutic areas including immunology, hepatology, pulmonology, hematology, and neurology. Grifols operates an extensive global network of plasma donor centers, specialized manufacturing facilities, and commercial subsidiaries, delivering plasma proteins, transfusion diagnostics, and hospital pharmacy logistics systems to medical centers and healthcare providers in more than 110 countries worldwide.
Resumo
Operações
Produtos e/ou serviços de Grifols
- Biopharma Plasma Therapies: Development and manufacturing of plasma-derived immunoglobulins, human albumin, alpha-1 antitrypsin, and clotting factors. These therapeutic proteins treat rare, chronic, and genetic conditions including primary immunodeficiencies, neurological disorders, alpha-1 antitrypsin deficiency, and bleeding disorders globally.
- Diagnostic Solutions: Production and distribution of blood screening systems, nucleic acid testing technology, reagents, and immunohematology instrumentation. These clinical laboratory products perform blood typing and detect infectious disease pathogens in donor blood supplies for hospital transfusion centers and diagnostic laboratories.
- Bio Supplies: Supply of raw human biological materials, intermediate plasma fractions, and customized biological products. The division provides plasma samples, cell lines, and specialty serum to pharmaceutical companies, biotechnology firms, and academic institutions for research, development, and diagnostic manufacturing.
- Healthcare Solutions for Hospitals: Provision of automated pharmacy systems, intravenous compounding software, cleanroom systems, and enteral nutrition products. These clinical workflows and technologies assist hospital pharmacies and clinical departments in managing medication preparation, patient administration, and hospital specialized fluids.
- Plasma Collection Infrastructure: Operation of a global network of specialized donor centers across North America and Europe. Facilities collect, test, and store human source plasma used as raw material for industrial fractionation and biopharmaceutical manufacturing plants.
- Engineering and Manufacturing Systems: Design, engineering, and manufacturing of specialized biopharmaceutical machinery, sterile process equipment, and cleanroom installations. Services cover process engineering, facility automation, and equipment maintenance for internal plasma processing facilities and third-party healthcare clients.
equipe executiva do Grifols
- Jose Ignacio Abia BuenacheCEO & Director
- Rahul SrinivasanChief Financial Officer
- Lluis Pons GomezSenior Vice President of Strategy & COO Office
- Daniel SegarraHead of Investor Relations & Sustainability and Vice President
- David Ian BellChief Corporate Affairs & Legal Officer
- Enrique de la TorreChief Compliance Officer
- Montse RibasChief Communications and Reputation Officer
- Camille AlpiChief Human Resources & Talent Officer
- Vicente Blanquer TorreChief Quality Officer
- Ignacio Ramal SubiraChief Internal Audit & Enterprise Risk Manager
Últimas notícias sobre a Grifols
Histórico de dividendos
Dividendos por ação pagos pela Grifols , por ano fiscal.
| Ano fiscal | Intermediário | Final | Especial | Total |
|---|---|---|---|---|
| FY2026(até o momento) | — | — | — | $0.0940 |
| FY2025 | — | — | — | $0.1730 |
| FY2021 | — | — | — | $0.4560 |
| FY2020 | — | — | — | $0.2010 |
| FY2019 | — | — | — | $0.3940 |
Principais indicadores financeiros
Resultados divulgados pela Grifols , em EUR.
- Cap. de mercado
- 5,5 bi
- Receita (TTM)
- 7,4 bi
- P/L
- 10.5
- LPA (diluído, TTM)
- 0.8
- Dividend yield
- —
- Margem de lucro
- 6.1%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 7,2 bi | 1,2 bi | 386,1 mi | |
| 7,2 bi | 1,2 bi | 156,9 mi | |
| 6,6 bi | 782,3 mi | 42,3 mi | |
| 6,1 bi | 782,4 mi | 185 mi |